Selank Peptide

Clinical and preclinical studies demonstrate Selank anxiolytic effects comparable to benzodiazepines but without sedation, cognitive impairment, or dependence:

• Reduced anxiety scores in generalized anxiety disorder patients (Phase 3, Russia)
• No sedation, no muscle relaxation, no dependence formation
• Preserved cognitive function — enhanced memory consolidation during anxiolysis
• Effective via intranasal route (high CNS bioavailability)

As a tuftsin analog, Selank retains and enhances the immunomodulatory properties of the parent molecule. Research demonstrates: enhanced phagocytic activity of monocytes and macrophages, increased NK cell cytotoxicity, modulation of IL-6 and TNF-alpha production, and restoration of T-cell subpopulation ratios in immunosuppressed models. This dual anxiolytic-immunomodulatory profile is unique among anti-anxiety compounds.

Whole-transcriptome analysis (Zainullina et al.) revealed Selank modulates expression of 36 genes in hippocampal tissue within 1 hour of administration. Key clusters include: GABAergic neurotransmission genes, serotonin metabolism enzymes, immune response mediators (MHC class I), and BDNF signaling pathway components. This broad transcriptomic signature explains the multi-modal activity profile.

Beyond anxiolysis, Selank demonstrates nootropic properties in multiple cognitive domains. Research findings include: enhanced spatial memory in Morris water maze (hippocampus-dependent), improved passive avoidance retention (amygdala-dependent), potentiation of long-term potentiation (LTP) in hippocampal CA1, and restoration of scopolamine-impaired memory (cholinergic model). The cognitive enhancement appears to be mediated through BDNF upregulation in hippocampal formation rather than direct neurotransmitter effects.

An unexpected finding in Selank research is its antiviral activity. Studies demonstrate Selank inhibits influenza A virus replication in vitro and in vivo, modulates interferon-gamma and IL-6 expression during viral infection, and enhances innate antiviral immune responses. The mechanism appears related to its tuftsin-derived immunostimulatory activity — enhanced phagocytic and NK cell function improve viral clearance. This dual anxiolytic-antiviral profile is unique and suggests value in psychoneuroimmunology research.

Microarray analysis of Selank-treated hippocampal tissue revealed modulation of key neurotransmitter system genes within 1 hour of administration. Significant changes were found in:

• GABAergic system: Upregulation of GABA-A receptor subunit genes (GABRA1, GABRB2, GABRG2), explaining the anxiolytic effect without direct receptor agonism
• Serotonergic system: Modulation of tryptophan hydroxylase (TPH2) and 5-HT transporter (SLC6A4), altering serotonin synthesis and reuptake dynamics
• Dopaminergic system: Changes in tyrosine hydroxylase (TH) expression in VTA neurons, potentially contributing to motivational effects
• Opioid system: Stabilization of proenkephalin (PENK) and prodynorphin (PDYN) mRNA, supporting endogenous opioid tone

This broad transcriptomic signature explains why Selank produces effects across multiple domains (anxiety, cognition, immunity) despite being a simple heptapeptide — it acts as a transcriptional modulator rather than a single-target drug.

Phase 3 clinical data from Russian registration trials demonstrated Selank efficacy in generalized anxiety disorder (GAD) and neurasthenia (chronic fatigue syndrome equivalent). Key findings from multi-center trials:

• Hamilton Anxiety Scale (HAM-A) scores reduced by 40-50% after 14 days of intranasal Selank (0.15% solution, 3 drops per nostril, 3x daily)
• Response rates (>50% HAM-A reduction): 62% for Selank vs 18% placebo
• No rebound anxiety upon discontinuation — effects sustained for 1-2 weeks post-treatment
• No sedation, cognitive impairment, or psychomotor slowing at any tested dose
• Concurrent improvement in fatigue, concentration, and sleep quality (secondary endpoints)

Safety profile across all trials: no serious adverse events, no dependence, no withdrawal syndrome. The most common side effect was mild nasal irritation (12% of subjects) which resolved without treatment.

A foundational body of preclinical research has examined Selank's anxiolytic properties using well-validated behavioral paradigms in animal models. The elevated plus maze (EPM), open field test, and conflict paradigms have all been employed to characterize Selank's effects on anxiety-like behavior.

In a series of studies conducted by Seredenin and colleagues at the Zakusov Institute, Selank was administered to inbred BALB/c mice, a strain genetically predisposed to high anxiety-like behavior. Key findings from these investigations include:

• Elevated Plus Maze: Selank-treated mice showed a significant increase in time spent in open arms of the EPM, with reported increases of 30–50% compared to vehicle-treated controls, indicative of reduced anxiety-like behavior.
• Absence of Sedation: Unlike the reference benzodiazepine diazepam, Selank did not reduce locomotor activity in the open field test, confirming an anxiolytic effect without sedative confounds.
• No Tolerance Development: Repeated administration of Selank over 14 days did not show diminished anxiolytic response, in contrast to benzodiazepines which typically exhibit tolerance within 5–7 days of continuous dosing.
• Strain Specificity: The anxiolytic response to Selank was more pronounced in BALB/c mice than in C57BL/6 mice, suggesting a genotype-dependent effect possibly related to baseline differences in GABAergic and serotonergic tone.

These preclinical findings established the pharmacological basis for Selank's subsequent clinical evaluation and differentiated it from classical GABAergic anxiolytics by demonstrating that anxiolytic efficacy could be achieved without the side-effect burden of benzodiazepine-class compounds.

Given Selank's structural relationship to tuftsin—an endogenous stimulator of phagocytosis—considerable research has explored its immunomodulatory properties. A genome-wide study by Ershov et al. (2009) examined the effects of Selank administration on gene expression profiles in the spleens of BALB/c and C57BL/6 mice using oligonucleotide microarrays.

Key findings from this investigation included:

• Selank significantly modulated the expression of 36 genes involved in immune signaling in BALB/c mouse spleens, including genes encoding cytokines, chemokines, and their receptors.
• Specific genes affected included IL-6, chemokine (C-C motif) ligand 2 (CCL2/MCP-1), and chemokine (C-X-C motif) receptor 5 (CXCR5).
• The peptide downregulated several pro-inflammatory mediators while simultaneously upregulating genes associated with protective immunity, suggesting an immunomodulatory rather than purely immunostimulatory profile.
• Gene expression changes were observed within 1 hour of Selank administration, indicating a rapid transcriptional response.

These findings suggest that Selank retains and expands upon the immunological activity of its parent tetrapeptide tuftsin, with a more complex and nuanced regulatory effect on immune gene networks. The simultaneous dampening of excessive inflammation and enhancement of protective immune pathways has implications for research into stress-associated immunosuppression, where anxiety and immune dysfunction frequently co-occur.

A landmark transcriptomic study by Volkova et al. (2016) investigated the genome-wide effects of Selank on gene expression in the hippocampus of BALB/c mice using high-throughput RNA sequencing. The hippocampus was selected as the target tissue due to its central role in anxiety regulation, memory consolidation, and neurotransmitter integration.

The study utilized RNA-Seq to profile mRNA expression changes following intranasal administration of Selank. The principal findings were:

• Selank significantly altered the expression of 36 genes in the hippocampus at 1 hour and 60 genes at 3 hours post-administration.
• Functional enrichment analysis revealed that affected genes clustered in pathways related to GABAergic neurotransmission, serotonin receptor signaling, ion channel function, and neuropeptide processing.
• Specifically, Selank modulated the expression of GABA_A receptor subunit genes (Gabra2, Gabra6, Gabrb1, Gabrg1), suggesting remodeling of receptor subunit composition that may alter GABA sensitivity.
• Several serotonin receptor genes, including Htr1a (5-HT_1A) and Htr2c (5-HT_2C), were among differentially expressed transcripts, providing molecular support for Selank's reported effects on serotonergic neurotransmission.
• The gene encoding BDNF showed a trend toward upregulation, consistent with the peptide's neurotrophic properties.

This study provided the first comprehensive, unbiased transcriptomic map of Selank's molecular effects in a brain region critical for anxiety and cognition. The data support a model in which Selank exerts its behavioral effects through coordinated transcriptional regulation of multiple neurotransmitter systems rather than acting on a single molecular target.

Selank has been evaluated in clinical settings in the Russian Federation for the management of generalized anxiety disorder (GAD) and neurasthenia-spectrum conditions. The most significant clinical data come from open-label and randomized controlled trials conducted at Russian medical institutions that supported the regulatory approval of intranasal Selank (0.15% solution).

In a clinical study by Zozulya et al. (2008), patients diagnosed with GAD (ICD-10: F41.1) and neurasthenia (F48.0) were administered intranasal Selank over a treatment period of 14 days. Outcomes were assessed using the Hamilton Anxiety Rating Scale (HAM-A) and the Spielberger State-Trait Anxiety Inventory (STAI). Key results included:

• Patients receiving Selank demonstrated a statistically significant reduction in HAM-A total scores, with a mean reduction of approximately 30% from baseline.
• Improvements were observed across both psychic anxiety and somatic anxiety subscales of the HAM-A.
• STAI state anxiety scores showed significant decreases beginning at day 3 of treatment, with continued improvement through day 14.
• No sedation, cognitive impairment, or psychomotor slowing was reported by patients receiving Selank, in contrast to benzodiazepine comparator groups.
• No withdrawal symptoms or rebound anxiety were observed upon treatment discontinuation.
• Tolerability was rated as "good" or "excellent" in >95% of patients.

These clinical observations are consistent with the preclinical pharmacological profile of Selank and provide preliminary evidence supporting its utility as a non-sedating anxiolytic. It should be noted that these studies were conducted primarily within the Russian medical system, and large-scale Phase 3 trials conforming to ICH-GCP standards have not been published in Western peer-reviewed journals. Further international clinical investigation would be required to establish the generalizability of these findings.

Building on the immunomodulatory foundation of its parent peptide tuftsin, Selank has been investigated for potential antiviral properties, particularly in the context of influenza virus infection. Research conducted at the Gamaleya Research Institute explored Selank's effects on influenza A virus replication and host immune defense parameters.

In a study by Ershov et al. (2009), the antiviral effects of Selank were examined in cell culture models of influenza A infection. Key observations included:

• Selank treatment was associated with enhanced expression of interferon-stimulated genes (ISGs), which play a critical role in the innate antiviral immune response.
• Selank modulated the expression of genes encoding inflammatory mediators, including IL-6 and TNF-α, in a pattern consistent with enhanced antiviral defense without excessive inflammatory pathology.
• In vivo studies in mice challenged with influenza A virus demonstrated that Selank-treated animals exhibited reduced viral titers in lung tissue compared to untreated controls.
• The antiviral effect appeared to be mediated primarily through enhancement of innate immune surveillance rather than direct viricidal activity, consistent with Selank's immunomodulatory mechanism.

These findings suggest that Selank's immunomodulatory activity extends to antiviral defense, potentially through upregulation of interferon pathways and optimization of innate immune responses. This dual anxiolytic-immunomodulatory profile may be of particular interest in research models examining the interaction between psychological stress and susceptibility to viral infection, an area of growing interest in psychoneuroimmunology.

Multiple preclinical studies have investigated Selank's effects on cognitive function, particularly learning and memory processes. The peptide's influence on BDNF expression and monoaminergic neurotransmission provides a mechanistic rationale for its reported nootropic properties.

Kozlovskii and Danchev (2003) examined the effects of Selank on conditioned active avoidance reflex (CAAR) acquisition in rats, a standard behavioral model for associative learning. The study findings included:

• Selank administration at doses of 100–300 µg/kg significantly accelerated the acquisition of the conditioned avoidance response compared to saline controls.
• The peptide demonstrated an optimizing effect—improving learning in initially poor-performing animals without impairing the performance of animals that already performed well.
• The effect persisted for 24 hours after a single administration, suggesting engagement of consolidation processes rather than simple state-dependent performance enhancement.
• Co-administration with the protein synthesis inhibitor cycloheximide partially blocked Selank's memory-enhancing effect, indicating involvement of de novo protein synthesis in the mechanism.

Additional research has explored Selank's effects in passive avoidance paradigms and Morris water maze spatial navigation tasks, consistently reporting improvements in both acquisition and retention phases. The cognitive-enhancing profile of Selank, combined with its anxiolytic properties, positions it as a compound of interest in research models of anxiety-related cognitive impairment, where elevated anxiety typically degrades cognitive performance through hippocampal dysfunction.